Showing 831-840 of 1211 results for "".
- Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMAhttps://modernod.com/news/omeros-announces-agreement-with-fda-on-primary-endpoint-for-narsoplimab-bla-in-stem-cell-transplant-associated-tma/2476724/Omeros announced agreement with the FDA on the response-based primary endpoint for its pivotal trial to support the biologics license application (BLA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ac
- Moorfields Dubai Hosts ‘World Association of Eye Hospitals’ Board Meetinghttps://modernod.com/news/moorfields-dubai-hosts-world-association-of-eye-hospitals-board-meeting/2479783/Dubai, the first overseas branch of the renowned Moorfields Eye Hospital London, will host the 2018 board meeting of the World Association of Eye Hospitals on Sunday November 4 at Moorfields Eye Hospital Dubai, which is located in Dub
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- Bausch + Lomb Presents New Data at the Association for Research in Vision and Ophthalmology Annual Meetinghttps://modernod.com/news/bausch-lomb-presents-new-data-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting/2482250/Bausch + Lomb announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Seattle on May 5-9, 2024. The posters highlight the results of studies evaluating consumer,
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Ocugen's OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of RP Associated with RHO Mutationshttps://modernod.com/news/ocugens-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-rp-associated-with-rho-mutations/2482019/Ocugen announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT designation is a significant accomplishment for the OCU400 clinical develo
- International Sports Vision Association Announces Leadership Appointments OF NEW EXECUTIVE AND ADVISORY BOARD OFFICERShttps://modernod.com/news/international-sports-vision-association-announces-leadership-appointments-of-new-executive-and-advisory-board-officers/2481491/The International Sports Vision Association (ISVA) announced the appointments of its new Executive and Advisory Board members, effective April 1, 2023. Executive Board Alireza Somji, OD assumes the position of President, succeeding Charles Shidlofsky, OD, FCOV
- The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Carehttps://modernod.com/news/the-american-diabetes-association-and-genentech-partner-to-increase-equitable-access-to-eye-health-care/2481482/The American Diabetes Association (ADA) and Genentech announced a new partnership as part of the ADA’s Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes communit
- FDA Clears IND Application for Huidagene Therapeutics' RPE65 Mutation-Associated Inherited Retinal Dystrophieshttps://modernod.com/news/fda-clears-ind-application-for-huidagene-therapeutics-rpe65-mutation-associated-inherited-retinal-dystrophies/2481373/HuidaGene Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for the planned multi-national clinical trial of HG004 for the treatment of patients suffering from RPE65 mutation-associated inherited retinal dystrophies.
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated